Maria Alimova

Maria Alimova, Ph.D.

Maria Alimova

Maria Alimova is a senior research scientist leading the High Content Screening (HCS) group in the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard, working under the direction of Joe Growney. Her group is participating in a number of CDoT drug discovery projects, related to cardiovascular disease, kidney pathology, cancer, and others using the state-of-the-art imaging approaches to identify and quantify a disease phenotype on a cell and tissue level, validating these findings using genetic perturbations in cells as well as in more complicated disease models, like human patient-derived organoids and genetically modified animals. The HCS group uses the cell image-based disease phenotype to develop HCS assays to perform screening of chemical molecules and genetic perturbations in a high throughput format. She also consults on multiple imaging projects all around the Broad Institute and other Harvard and MIT affiliates.

Alimova came to the Broad Institute in 2015 after working at the Belfer Institute for Applied Cancer Science (BIACS) at the Dana-Farber Cancer Institute in Boston. Prior to that position, she was a senior research scientist at the Institute for Applied Cancer Science (IACS) of the MD Anderson Cancer Center in Houston, Texas.

Alimova holds a Ph.D. in molecular biology from the Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow. She completed her postdoctoral training at the Karolinska Institute in Stockholm, Sweden.

Contact Maria Alimova via email at

January 2021